CD274 and non-small cell lung carcinoma: PACIFIC was a randomized, double-blind, placebo-controlled Phase III trial that evaluated the efficacy of immunotherapy with a PD-L1 inhibitor (durvalumab) in patients with unresectable stage III NSCLC that had not progressed after concurrent CRT [1].